EUVIMEDEUVIMED entdecken
Multizentrische Studie

Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study

Dharmesh Gopalakrishnan, Yu Fujiwara, Katharine A Collier, Joseph J Park, Jacob P Zaemes, Elaine T Lam, Sabah Alaklabi, Ellen B Jaeger, Pedro C Barata, Eric C Kauffman, Michael B Atkins, Ajjai Alva und 2 weitere

Journal of the National Comprehensive Cancer Network · 2026-11 · 24 (11)

DOI: 10.6004/jnccn.2026.7058 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-11. Verfasst von Dharmesh Gopalakrishnan und 13 weiteren Autor:innen. Beteiligte Einrichtung: 1Roswell Park Comprehensive Cancer Center, Buffalo, NY. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic sarcomatoid renal cell carcinoma (msRCC) is an aggressive disease typically associated with poor outcomes following VEGF-targeted therapies. This study evaluated in real-world outcomes in patients with msRCC based on whether they received treatment with immune checkpoint inhibitors (ICIs).

Methods

We conducted a multi-institutional, retrospective study of patients who received systemic therapy for msRCC between July 2010 and June 2020. In total, 203 patients across 6 US academic centers were included. Patients were categorized into 2 groups based on whether they received ICIs: ICI+ (n=155) and ICI− (n=48). Overall survival (OS) was estimated using the Kaplan–Meier method and measured from the initiation of frontline systemic therapy. Treatment responses were evaluated by investigators at participating centers.

Results

After a median follow-up of 48.1 months, OS was significantly longer in the ICI+ group (median OS, 31.0 vs 7.6 months; hazard ratio [HR], 0.38; 95% CI, 0.26–0.56; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsImmune Checkpoint InhibitorsHumansRetrospective StudiesFemaleMaleMiddle AgedAgedCell DedifferentiationAdult

Stichwörter der Autor:innen

Metastatic renal cell carcinomaimmune checkpoint inhibitorssarcomatoid dedifferentiationtyrosine kinase inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • 1Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • 2Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
  • 3Medical College of Wisconsin Cancer Center, Milwaukee, WI.
  • 4The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • 5University of Michigan Rogel Cancer Center, Ann Arbor, MI.
  • 6Duke Cancer Institute, Durham, NC.

Zitieren

APA

Gopalakrishnan, D., Fujiwara, Y., Collier, K. A., Park, J. J., Zaemes, J. P., Lam, E. T., Alaklabi, S., Jaeger, E. B., Barata, P. C., Kauffman, E. C., Atkins, M. B., Alva, A., Yang, Y., & George, S. (2026). Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study. Journal of the National Comprehensive Cancer Network, 24(11). https://doi.org/10.6004/jnccn.2026.7058

Vancouver

Gopalakrishnan D, Fujiwara Y, Collier KA, Park JJ, Zaemes JP, Lam ET, et al. Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study. Journal of the National Comprehensive Cancer Network. 2026;24(11). doi:10.6004/jnccn.2026.7058

BibTeX
@article{Gopalakrishnan2026,
  author = {Gopalakrishnan, Dharmesh and Fujiwara, Yu and Collier, Katharine A and Park, Joseph J and Zaemes, Jacob P and Lam, Elaine T and Alaklabi, Sabah and Jaeger, Ellen B and Barata, Pedro C and Kauffman, Eric C and Atkins, Michael B and Alva, Ajjai and Yang, Yuanquan and George, Saby},
  title = {Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  volume = {24},
  number = {11},
  doi = {10.6004/jnccn.2026.7058}
}
Kostenlos starten →